Philippines Lawmaker Says WTO Rules Slipped Into Cheap Medicines Bill
This article was originally published in PharmAsia News
Executive Summary
A representative in the Philippines House says a drug industry consultant revealed that provisions sneaked into a "cheap-medicines" bill approved by the House would moot its effects. The measure is intended to make drugs more competitive and thus bring about lower prices. But one of the bill's supporters said he was told by the consultant that provisions had been slipped into the bill to make provisions of a World Trade Organization agreement paramount to local law and thus block Indian generics. The provisions are in the Trade Related Aspects of Intellectual Property Rights agreement that allows multinationals to patent their drugs in India. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.